Guardant Health Named to TIME’s List of the Best Inventions of 2024
Guardant Health's blood-based colorectal cancer screening product Shield has been named to TIME's Best Inventions of 2024 list. Shield, which is the first FDA-approved and Medicare-reimbursed colorectal cancer screening blood test, was recognized among 200 extraordinary innovations. The company recently achieved significant milestones, including 500 peer-reviewed publications and over 500,000 patient tests delivered. Shield received FDA approval in July 2024 and subsequent Medicare reimbursement, marking a significant advancement in early cancer detection technology.
Shield, il prodotto di screening del cancro colon-rettale basato sul sangue di Guardant Health, è stato inserito nella lista delle Best Inventions of 2024 di TIME. Shield, il primo test del sangue approvato dalla FDA e rimborsato da Medicare per lo screening del cancro colon-rettale, è stato riconosciuto tra 200 innovazioni straordinarie. L'azienda ha recentemente raggiunto traguardi significativi, tra cui 500 pubblicazioni sottoposte a revisione paritaria e oltre 500.000 test effettuati sui pazienti. Shield ha ricevuto l'approvazione della FDA a luglio 2024 e il successivo rimborso da Medicare, segnando un importante progresso nella tecnologia di rilevamento precoce del cancro.
El producto de detección de cáncer colorrectal basado en sangre de Guardant Health, Shield, ha sido incluido en la lista de Las Mejores Invenciones de 2024 de TIME. Shield, que es la primera prueba de sangre para el cáncer colorrectal aprobada por la FDA y reembolsada por Medicare, fue reconocida entre 200 innovaciones extraordinarias. La empresa ha alcanzado recientemente hitos significativos, incluidos 500 publicaciones revisadas por pares y más de 500,000 pruebas realizadas a pacientes. Shield recibió la aprobación de la FDA en julio de 2024 y el posterior reembolso de Medicare, marcando un avance significativo en la tecnología de detección temprana del cáncer.
Guardant Health의 혈액 기반 대장암 선별 제품인 Shield가 TIME의 2024년 최고의 발명 목록에 이름을 올렸습니다. Shield는 FDA에서 승인받고 Medicare에서 환급되는 첫 번째 대장암 선별 혈액 검사로, 200개의 뛰어난 혁신 중에서 인정받았습니다. 이 회사는 최근 500개의 동료 검토 출판물과 500,000건 이상의 환자 테스트를 완료하는 등 중요한 이정표를 달성했습니다. Shield는 2024년 7월에 FDA 승인을 받았고, 이후 Medicare에서 환급을 받으며 조기 암 탐지 기술의 중요한 발전을 이뤘습니다.
Le produit de dépistage du cancer colorectal basé sur le sang de Guardant Health, Shield, a été nommé dans la liste des Meilleures Inventions de 2024 du TIME. Shield, qui est le premier test sanguin de dépistage du cancer colorectal approuvé par la FDA et remboursé par Medicare, a été reconnu parmi 200 innovations extraordinaires. L'entreprise a récemment franchi des étapes importantes, notamment 500 publications évaluées par des pairs et plus de 500 000 tests réalisés sur des patients. Shield a reçu l'approbation de la FDA en juillet 2024 et le remboursement suivant de Medicare, marquant une avancée significative dans la technologie de détection précoce du cancer.
Das blutbasierte Screening-Produkt für kolorektale Krebs von Guardant Health mit dem Namen Shield wurde in die Liste der Besten Erfindungen 2024 von TIME aufgenommen. Shield, der erste von der FDA zugelassene und von Medicare erstattete Bluttest zur Darstellung von kolorektalem Krebs, wurde unter 200 außergewöhnlichen Innovationen anerkannt. Das Unternehmen hat kürzlich bedeutende Meilensteine erreicht, darunter 500 begutachtete Veröffentlichungen und über 500.000 durchgeführte Patiententests. Shield erhielt im Juli 2024 die FDA-Zulassung und die anschließende Erstattung durch Medicare, was einen bedeutenden Fortschritt in der Technologie zur frühzeitigen Krebsdiagnose darstellt.
- Shield received FDA approval and Medicare reimbursement
- Recognition in TIME's Best Inventions list enhances product credibility
- Milestone achievement of 500,000 patient tests delivered
- Reached 500 peer-reviewed publications
- None.
Shield™, the first FDA-approved, Medicare-reimbursed colorectal cancer screening blood test, named to the Medical Care list
To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields—such as health care, AI, and green energy. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.
“We’re honored to be a part of this prestigious list of leading innovative products that are making a dramatic difference in how we live our lives today,” said AmirAli Talasaz, co-CEO and co-Founder of Guardant Health. “We created Guardant Health with the vision to detect and characterize cancer across the spectrum, and now we are able to do this with colorectal cancer at earlier stages with the launch of Shield. This has the opportunity to transform cancer detection and save millions of lives.”
Of the new list, TIME’s editors write: “The result is a list of 200 groundbreaking inventions (and 50 special mention inventions)—including the world's largest computer chip, a humanoid robot joining the workforce, and a bioluminescent houseplant—that are changing how we live, work, play, and think about what’s possible.”
Guardant recently reached several significant milestones, including announcing that it has achieved 500 peer-reviewed publications and more than 500,000 patient tests delivered. Shield was approved by the Food and Drug Administration in July 2024, and reimbursed by Medicare shortly thereafter.
See the full list here: time.com/best-inventions-2024
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn and X (Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030233321/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Melissa Marasco
press@guardanthealth.com
Source: Guardant Health, Inc.
FAQ
When did Guardant Health's Shield receive FDA approval?
How many patient tests has Guardant Health (GH) delivered?
What is Guardant Health's Shield blood test used for?
Is Guardant Health's Shield test covered by Medicare?
